文献速递白血病

抑制MAPK通路可逆转急性髓系白血病诱导的T细胞抑制

Acute myeloid leukemia-induced T-cell suppression can be reversed by inhibition of the MAPK pathway.
PubMed 文献 · Blood Adv · 2019-01-01

该研究利用免疫抑制性AML小鼠模型和原代患者样本,探讨曲美替尼对T细胞和AML原始细胞的影响,并结合大型AML功能药物筛选数据库分析曲美替尼敏感样本的特征。结果显示曲美替尼提高T细胞活力、恢复增殖,敏感样本呈炎症基因表达谱且PD-L1表达升高,曲美替尼剂量依赖性降低髓系细胞PD-L1和PD-L2表达。

要点

  • 曲美替尼可提高AML小鼠模型中T细胞活力并恢复其增殖。
  • 曲美替尼敏感AML样本呈炎症基因表达谱且PD-L1表达升高。
  • 曲美替尼剂量依赖性降低髓系细胞PD-L1和PD-L2表达。

核心结论

  • 曲美替尼可逆转AML诱导的T细胞抑制,并调节免疫检查点分子表达。

研究设计与样本

  • 研究采用免疫抑制性AML小鼠模型和原代患者样本,并结合大型AML功能药物筛选数据库进行分析。

主要发现

  • 在小鼠模型中,曲美替尼增加T细胞活力并恢复T细胞增殖。
  • 曲美替尼促进CD8+CD44+效应亚群增殖,但损害CD8+CD62L+初始细胞的活化。
  • 转录组分析显示曲美替尼敏感样本具有炎症基因表达谱,且其PD-L1表达增加。
  • 曲美替尼以剂量依赖性方式持续降低髓系细胞PD-L1和PD-L2表达。

临床怎么用

  • 曲美替尼可能通过调节免疫微环境增强AML免疫治疗疗效,支持其与免疫疗法联合的进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) remains difficult to treat due to mutational heterogeneity and the development of resistance to therapy. Targeted agents, such as MEK inhibitors, may be incorporated into treatment; however, the impact of MEK inhibitors on the immune microenvironment in AML is not well understood. A greater understanding of the implications of MEK inhibition on immune responses may lead to a greater understanding of immune evasion and more rational combinations with immunotherapies. This study describes the impact of trametinib on both T cells and AML blast cells by using an immunosuppressive mouse model of AML and primary patient samples. We also used a large AML database of functional drug screens to understand characteristics of trametinib-sensitive samples. In the mouse model, trametinib increased T-cell viability and restored T-cell proliferation. Importantly, we report greater proliferation in the CD8+CD44+ effector subpopulation and impaired activation of CD8+CD62L+ naive cells. Transcriptome analysis revealed that trametinib-sensitive samples have an inflammatory gene expression profile, and we also observed increased programmed cell death ligand 1 (PD-L1) expression on trametinib-sensitive samples. Finally, we found that trametinib consistently reduced PD-L1 and PD-L2 expression in a dose-dependent manner on the myeloid population. Altogether, our data present greater insight into the impact of trametinib on the immune microenvironment and characteristics of trametinib-sensitive patient samples.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Moshofsky KB, Cho HJ, Wu G, et al. Acute myeloid leukemia-induced T-cell suppression can be reversed by inhibition of the MAPK pathway. Blood Adv. 2019. PMID: 31648326. doi:10.1182/bloodadvances.2019000574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。